Filing Flows › Bruker (BRKR) › Q3 2025
Bruker (BRKR) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Bruker (BRKR) reported revenue of $860M for the third quarter 2025 (Q3 2025), -0.5% from a year earlier and +8% from the quarter before. Operating margin was -6.0%, net loss $58.5M (6.8% of revenue).
Bruker, Q3 2025: revenue $860M (-0.5% year over year), operating margin -6.0%, net loss $58.5M, operating cash flow −$33.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $860M | +8% | -0.5% |
| Operating profit | −$51.8M | -535% | — |
| Net earnings | −$58.5M | -870% | — |
| Operating cash flow | −$33.2M | — | — |
What changed
Revenue was $860.5M in Q3 2025, roughly flat year over year and up 8% from the previous quarter. Bsi Calid was the largest line at 36% of revenue. Bsi Biospin lost $24.3M year over year (down 10%), 623% of the total change.
Gross margin was 44.1%, down 4.4 points from a year earlier. Operating costs exceeded revenue by $51.8M, an operating margin of -6.0%. Operating expenses grew 23% against flat revenue. The fastest-growing cost line was Other operating costs (+298%). The quarter ended with a net loss of $58.5M, after a profit of $4.2M the previous quarter.
Operating cash flow was −$33.2M. Non-cash charges added back $55.7M of depreciation and amortization and $6.0M of share-based compensation. Working capital and other items used $36.4M. Capital expenditures of $20.9M exceeded it, leaving free cash flow of −$54.1M.
Questions
What was Bruker's revenue in the third quarter 2025?
Bruker (BRKR) reported revenue of $860M for the third quarter 2025 (Q3 2025), -0.5% from a year earlier and +8% from the quarter before.
Was Bruker profitable in the third quarter 2025?
Operating loss was $51.8M (-6.0% of revenue) and net loss $58.5M.
Source: Bruker 10-Q on SEC EDGAR.